Histological Evaluation of BTL-899 Device´s Effect on Fat Tissue

Fat Burn Clinical Trial

Official title:

Histological Evaluation of BTL-899 Device´s Effect on Fat Tissue

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT05139745
• Other study ID #: BTL-899_CTUS400
• Status: Completed
• Phase: N/A
• Start date: October 11, 2021
• Est. completion date: August 11, 2022

Study information

• Verified date: August 2022
• Source: BTL Industries Ltd.
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This study will evaluate the safety and performance of the BTL-899 device for non-invasive treatment of subcutaneous fat. The changes in the fat tissue related to the activity of caspase-3 will be assessed histologically. The study is a prospective single-center single-blinded two-arm study. The subjects will be enrolled and assigned into two study groups; Group A which will receive active treatment and Group B which receives sham treatment and will serve as a control to verify the treatment outcomes. Subjects will be required to complete only one (1) treatment visit and three (3) follow-up visits (at 8 hours, 24 hours and 7 days post treatment). All of the study subjects will receive the treatment (either active or sham) with the subject device. At the baseline visit, health status will be assessed. Inclusion and exclusion criteria will be verified and informed consent will be signed. Punch biopsies from the treated abdominal area will be taken to examine the changes related to caspase-3 activity.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 7
• Est. completion date: August 11, 2022
• Est. primary completion date: April 27, 2022
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: 21 Years and older

Eligibility

Inclusion Criteria:

• Age > 21 years
• Voluntarily signed an informed consent form
• BMI = 35 kg/m2
• Women of child-bearing potential are required to use birth control measures during the whole duration of the study.
• Willingness to abstain from partaking in any treatments other than the study procedure
• Willingness to comply with study instructions, to return to the clinic for the required visits and to undergo punch biopsies in the abdominal area.

Exclusion Criteria:

• Electronic implants (such as cardiac pacemakers, defibrillators, and neurostimulators)
• Metal implants in the treated area
• Drug pumps
• Malignant tumor
• Pulmonary insufficiency
• Injured or otherwise impaired muscles in the treated area
• Cardiovascular diseases
• Disturbance of temperature or pain perception
• Hemorrhagic conditions
• Septic conditions and empyema
• Acute inflammations in the treated area
• Systemic or local infection such as osteomyelitis and tuberculosis
• Contagious skin disease
• Elevated body temperature
• Application during pregnancy, postpartum period, nursing, and menstruation
• Graves' disease
• Skin related autoimmune diseases that may contradict the biopsy
• Poor healing and unhealed wounds in the treatment area
• Any disease or condition contradicting the skin tissue biopsy
• Any disease or condition that may compromise the histologic observation at the pathologist discretion

Related Conditions & MeSH terms

• Fat Burn

Intervention

Device:
• BTL-899
BTL-899 treatment

Locations

Country	Name	City	State
United States	Skin Laser and Surgery Specialist, a Division of Schweiger Dermatology	Hackensack	New Jersey

Sponsors (1)

Lead Sponsor	Collaborator
BTL Industries Ltd.

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Increased caspase-3 activity	Biopsy samples of the abdominal fat tissue will be processed for histological evaluation by a certified laboratory. Conventional staining will be used to determine the changes in the fat tissue related to the increase in caspase-3 activity, which is associated with elevated levels of fat tissue apoptosis, and to examine other morphological changes of treated tissue, in all collected samples. Post-treatment findings will be compared to the baseline. The results of both study groups will be compared as well.	1 month
Secondary	Safety assessment	Occurrence of adverse events	1 month